The purpose of the study is to determine the safety, tolerability, and plasma
pharmacokinetics (i.e., the levels of TMC589337 and TMC589354 circulating in your blood over
time) of increasing single oral doses of TMC589337 and TMC589354 and of multiple increasing
oral doses followed by a single dose of TMC310911 to assess the potential boosting effect on
the latter compound. In this study 3 investigational new drugs are involved. These new
investigational drugs called TMC589337 and TMC589354 (from the PEPI family) and TMC310911 are
in process of development for the treatment of Human Immunodeficiency Virus-Type 1 (HIV-1).
TMC589337 and TMC589354 are novel molecules with no antiviral activity to be used to enhance
the pharmacokinetics profile of a drug. TMC310911 is a novel and potent compound and belongs
to a medication class called protease inhibitors (PI).